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ALEFACEPT TREATMENT FOR CHRONIC EXTENSIVE GRAFT VERSUS
HOST DISEASE
Shapira, M.Y., Resnick, I.B., Bitan, M., Tsirigotis, P., Aker, M.,
Gesundeheidt, B., Slavin, S., Or, R. Hadassah – Hebrew University Med-
ical Center, Jerusalem, Israel.
Alefacept (Amevive) is an immunosuppressive dimeric fusion
protein that is used for psoriasis control. We have recently shown
its effect in acute, steroid resistant/dependent GVHD. In this study,
we describe the effect of alefacept treatment on chronic extensive
graft versus host disease (cGVHD). A total of 12 patients (13
cGVHD episodes) were included in this study, alefacept dose for
children and adults was 15 mg and 30 mg once weekly. A median
of 9 (range 1–25) injections were given per patient. Eight out of
12 patients (9/13 episodes) showed response. The median time to
initial response was 2.25 weeks (range 1–8). The response was either
marked (n5 3), moderate (n5 2) or minimal (n5 4). In 2 respond-
ing patients, the response was only temporary. Responding organs
included: skin, oral mucosa, eyes and lungs. Complications that ap-
peared during treatment included infection, pericarditis and squa-
mous cell carcinoma of the lip. All these events may be related to
other drugs given simultaneously. Seven of the twelve patients are
alive all with stable or improved cGVHD. Five patients died due
to GVHD progression while none of the patients experienced re-
lapse of the basic disease. As previously reported in psoriatic pa-
tients treated with alefacept, we found a consistent increase in the
percentage of naive T cells as a consequence of treatment. In con-
clusion, alefacept is effective for the treatment of cGVHD, dose
and treatment’s time intervals should be further explored.381
SILDENAFIL (REVATIO) THERAPY IN CHRONIC GRAFT VERSUS HOST
DISEASE (cGVHD): IMPROVEMENT IN PULMONARY cGVHD SYMPTOMS
Bauer, S.S., Dao, C., Cashen, A., Vij, R., Stockerl-Goldstein, K.,
Uy, G.L., Westervelt, P., DiPersio, J.F., Abboud, C.N. Washington Uni-
versity, St. Louis, MO.
Sildenafil (Revatio) has been used in patients with primary pul-
monary hypertension but its impact on the post allogeneic trans-
plant recipents with chronic lung graft versus host disease
(cGVHD) has not been well characterized. We have noted signifi-
cant improvement in an index case with peripheral acrocyanosis
and dyspnea. Since then we have treated 3 more patients with Reva-
tio as detailed in this report.
Patient 1: 55 yr with Aplastic Anemia 2 years s/p allogeneic pe-
ripheral blood stem cell transplant (PBSC) using single dose TBI
550 cGY/Cy 60 mg/kg. Treatment began on 05/15/06 owing to
acrocyanosis of fingertips and shortness of breath. She improved
dramatically with resolution of cyanotic fingertips and amelioration
of her dyspnea within 6 month of therapy. Patient 2: : 55 yr with
AML, 5 years s/p allogeneic PBSC transplant with single dose
TBI 550 cGY/Cy 60 mg/kg 2. She had aGVHD of skin in the first
100 days and developed symptoms of shortness of breath and cough
two years post transplant. Revatio 20 mg tid was begun on 11/2006
with marked improvement of her dyspnea. Patient 3: : 54 yr with
CML 20 months s/p allogeneic marrow stem cell transplant using
fractioned TBI 1200 cGY/Cy 60 mg/kg  2. She had mild GI
aGVHD and developed cough and shortness of breath 1 year post
transplant. Revatio 20 mg tid was started in January of 2007 with
improvement of shortness of breath. Patient 4: 44 yr, 6.5 years s/
p allogeneic PBSC transplant for CML, using single dose TBI
550 cGY/Cy 60 mg/kg  2. He had stage III aGVHD of the skin
and later cGVHD of lungs with cough and dyspnea late in 2006
and noted improvement in pulmonary symptoms. No flushing, di-
arrhea or visual changes were seen in these 4 patients and the
drug has been continued without dose reduction or interruption
in all patients at 20 mg TID. No overt changes in pulmonary
and/or cardiac function were demontrated in this cohort of patients,
indicating that Sildenafil actions may involve mild peripheral arte-
rial and venous vasodilatation in vivo and inhibition of platelets ag-
gregation leading to improved symtomatology. Further clinical
trials carefully monitoring quality of life instruments as well as car-diovascular and pulmonary reserve before and after treatment are
needed to determine the role of Sildenafil in patients with cGVHD.
Individual cardiac and pulmonary function tests are shown below:Cardiopulmonary Studies before and after Sildenafil
ECHO- ECHO-
Patient
#
PFT:
Pre-Revatio
PFT:
Post-Revatio
Pre-
Revatio
Post-
Revatio1 2.78 L 2.23 L Normal NA
2 2.52 L 1.16 L 73% NA
3 2.24 L 2.49 L 62% 60%
4 1.66 L 1.55 L Normal NAPulmonary artery pressure was 27,\30 and 50 mm Hg in patients 1,
2, 3.382
b2 INTERGRINS SEPARATES GRAFT-VERSUS-HOST DISEASE AND
GRAFT-VERSUS-LEUKEMIA EFFECT
Yu, X.-Z.1, Liang, Y.1, Liu, C.2, Djeu, J.Y.1, Zhong, B.1, Peters, T.3,
Scharffetter-Kochanek, K.3, Anasetti, C.1. 1 H. Lee Moffitt Cancer Center
& Research Institute, Tampa, FL; 2 University of Florida; 3 University of
Ulm, Germany.
Graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality in allogeneic hematopoietic stem cell
transplantation. Migration of donor-derived T cells into GVHD
target organs plays an essential role in the development of
GVHD. b2 integrins are critically important for leukocyte extrava-
sation through vascular endothelia and for T cell activation. We
asked whether CD18-deficient T cells would induce less GVHD
while sparing graft-versus-leukemia (GVL) effect. In murine alloge-
neic bone marrow transplantation models, we found that recipients
of CD18-/- donor T cells had significantly less GVHD morbidity
and mortality compared with recipients of WT donor T cells. Anal-
ysis of allo-reactivity showed that CD18-/- and WT T cells had
comparable activation, expansion and cytokine production in vivo.
Reduced GVHD was associated with a significant decrease in do-
nor-T cell infiltration of recipient intestine and with an overall de-
crease in pathologic scores in intestine and liver. Finally, we found
that in vivo GVL effect of CD18-/- donor T cells was largely pre-
served, because mortality of the recipients transplanted with
CD18-/- T cells plus tumor cells was greatly delayed or prevented.
Our data suggest that strategies to target b2 intergrin have clinical
potential to alleviate or prevent GVHD while sparing GVL activity.383
ELUCIDATING THE ROLE OF THE Fas-Fasl PATHWAY DURING CUTANE-
OUS GVHD ACROSS MINOR HISTOCOMPATIBILITY ANTIGENS IN VITRO
Arditti, F.D., Friedman, T., Korngold, R. Hackensack University Med-
ical Center, Hackensack, NJ.
The role of the Fas-FasL pathway in the pathological develop-
ment of graft-vs-host disease (GVHD) directed to miHA remains
unclear. We have recently established a new in vitro culture system
to study cutaneous GVHD in mice and used this system to test the
involvement of the Fas-FasL pathway. Primary epithelial cells
(pEC), constitutively expressing Fas, were obtained from ear skin
of BALB. B mice. Confluent pEC were co-cultured with unsepa-
rated T cells from MHC-matched, miHA-mismatched C57Bl/6
(B6) mice. Two days later, Fas expression was increased on the
pEC (58.76 8.8, as compared to 21.96 3.2 in pEC cultured alone,
p\0.03). To test whether pEC death observed by day 4 in co-cul-
tures was attributed at least in part to the up-regulated Fas, BALB. B
pEC were co-cultured with T cells derived from B6 gld -/gld - mice
(gld). Despite their FasL deficiency, gld T cells killed BALB. B pEC
140 Poster Session IIby day 4 as efficiently as wt B6 T cells, with a similar reduction in
pEC viability, from 93 6 6.7 to 43 6 6.4 in the presence of gld T
cells and 446 8.6 in the presence of wt B6 T cells (p . 0.5). How-
ever, upregulation of Fas on pEC co-cultured with gld T cells was
delayed and seen only by day 4 rather than day 2. The capacity of
gld T cells to modulate the epithelial environment appears intact,
since they induced the upregulation of H2Kb by 10-fold and IAb
by 3-fold on the pEC, similar to the effect induced by wt B6 T cells.
We also found higher interferon gamma (IFNg) in the supernatants
of co-cultures with gld T cells (141.26 17.8), as compared to wt B6
T cells (100.3 6 20.1, p\ 0.004). However, in contrast to the ex-
pression of H2Kb and IAb which were up-regulated 5.5-fold and
2.8-fold by IFNg added to pEC cultures, Fas expression was not al-
tered by this cytokine even after 7 days and at high doses (50 and 500
ng/ml). In summary, T cells increased the expression of Fas on
miHA-mismatched pEC. This event was of no evident conse-
quence, since FasL expression on ‘‘donor’’ T cells was not required
to kill ‘‘host’’ pEC in the 4-day period studied. FasL-deficient T
cells also modulated the expression of epithelial MHC molecules
and might be associated with the high levels of IFNg, a key cytokine
during GVHD, detected in supernatants of co-cultures. However,
IFNg did not regulate Fas on pEC, indicating that other cyto-
kines/mechanisms are responsible for this effect. Altogether, our re-
sults suggest that the Fas-FasL pathway may have a minor role in
the early pathogenesis of cutaneous GVHD.384
DACLIZUMAB AND INFLIXIMAB FOR TREATMENT OF STEROID RESIS-
TANT ACUTE GRAFT VERSUS HOST DISEASE (aGVHD) IN PEDIATRICS
Snyder, R.L., Daum, C., Klinger, E., Neudorf, S., Simpson, L. Children’s
Hospital of Orange County, Orange, CA.
Patients with steroid resistant aGVHD have a poor prognosis.
Daclizumab (anti-IL2 receptor alpha chain), and infliximab (anti-
TNF) have shown activity in early clinical trials in adults. We are
reporting our experience using daclizumab and infliximab in 3 pedi-
atric patients. All received daclizumab (1 mg/kg/dose IV on days 1,
4, 8, 15 and 22 and infliximab (10 mg/kg/dose IV on days 1, 8, 15
and 22). Steroid tapering was at the discretion of the attending phy-
sician based on clinical condition and response to treatment.
UPN 377 was a 19 month old girl with Hemophagocytic Lym-
phohistiocytosis who received a related bone marrow graft matched
for 8/8 alleles. She received a preparative therapy consisting of bu-
sulfan, VP16 and cytoxan and methotrexate (mtx) and cyclosporine
(csa) for GVHD prophylaxis. She developed stage 3 grade 2
aGVHD of the skin on d1 32 post transplant. After 19 days of ste-
roids (2 mg/kg/day), daclizumab and infliximab were started.
GVHD improved by d 1 36. The patient developed extensive
chronic GVHD and is presently 522 days post transplant with a Lan-
sky score of 100%.
UPN 394 was an 8 yr old male with ALL in CR2 who received
a related bone marrow graft matched for 5/8 alleles. He received
TBI, VP16 and cytoxan and mtx and csa for GVHD prophylaxis.
He developed stage 3 grade 2 aGVHD of the skin on d 1 24 post
transplant. After 2 days of steroids (4 mg/kg/day), he was treated
with daclizumab and infliximab. GVHD improved by d 1 31.
The patient has extensive chronic GVHD. He is 210 days post
transplant and has a Lansky score of 100%.
UPN 395 was a 13 month old male with ALL in CR1 who re-
ceived an unrelated bone marrow graft matched for 8/8 alleles.
He received TBI, VP16 and cytoxan and csa and mtx for GVHD
prophylaxis. He developed stage 3 grade 2 aGVHD of the skin on
d 1 19 post transplant. After 11 days of steroids (2 mg/kg/day),
he was treated with daclizumab and infliximab. GVHD improved
by d 1 33. The patient relapsed at d 1 189 post transplant and
has no signs of chronic GVHD.
In all patients, there were no instances of opportunistic viral or
fungal infections. This small series suggests that the combination
of daclizumab and infliximab is well tolerated and an effective ther-
apy for steroid resistant GVHD in pediatrics. Therefore, we have
revised our algorithm for the management of aGVHD (to be dis-
played at the meeting).385
MONOCYTE BLOOD COUNT AND ACUTE GVHD: FLOW CYTOMETRY
ANALYSIS RECOMMENDED IN PROSPECTIVE STUDIES
Chunduri, S.1, Arpinati, M.2, Singh, V.3, Shuaipaj, T.1, Mehta, J.3,
Rondelli, D.1. 1 University of Illinois at Chicago, Chicago, IL; 2 University
of Bologna, Bologna, Italy; 3 Northwestern University, Chicago, IL.
Patients with a high absolute number of peripheral blood CD141
monocytes prior to starting the conditioning regimen have been
shown to have a greater risk of developing acute graft-versus-host
disease (aGVHD) (Arpinati et al. BBMT 2007) after allogeneic he-
matopoietic stem cell transplantation (HSCT). In this study, we ini-
tially pooled the data of 154 consecutive patients with hematologic
malignancies who received an allogeneic peripheral blood stem cell
transplant at three different institutions, utilizing myeloablative (n
5 36) or reduced intensity conditioning (n5 118) regimens not in-
cluding ATG. The blood absolute monocyte count (AMC) was as-
sessed before starting the conditioning regimen and it was
calculated by dividing the absolute white cell count by the percent-
age of monocytes obtained with an automated CBC. The median
value of AMC in the study was 0.5  109/L (range:0.0–11.8). Of
154 patients, 73 had\ 0.5 and 81 had $0.5 AMC  109/L prior
to starting the conditioning regimen. All the patients received an
8/8 HLA antigen matched graft from related (n5 114) or unrelated
(n 5 40) donors. In the group of patients with lower AMC the me-
dian age was 51 (range:19–71) and donors were unrelated in 27%
and sex mismatched in 41% of the cases, whereas in the group of pa-
tients with higher AMC median age was 50 (range:18–63) and do-
nors were unrelated in 25% and sex mismatched in 36% of the
cases. The rate of acute GVHD grade II-IV in patients with low
or high AMC was 44% and 38%, respectively (p5ns). To test
whether the AMC obtained by means of automated CBC was com-
parable to the absolute count of CD141 monocytes detected by
flow cytometry, blood samples from 43 patients were analyzed uti-
lizing both techniques. In this series of patients, mean values of
AMC and CD141 blood cells were 11.9 6 11.9 and 7.3 6 6.9 
109/L and median values were 9.6 (range 95% CI:8.2–15.6) and
6.0 (range 95% CI:5.2–9.5)  109/L, respectively, (p 5 0.0004).
In this study, the analysis of monocyte absolute count by automated
CBC did not confirm the correlation between high levels of blood
CD141 cells analyzed by flow cytometry and development of
aGVHD. Since we demonstrate here that the absolute number of
monocytes obtained by cytofluorimetric expression of CD14 is sig-
nificantly different as compared to that obtained by automated
CBC, future prospective studies addressing the prognostic role of
monocyte blood count in allogeneic HSCT should be performed
utilizing a flow cytometry-based method.386
SIROLIMUS IN COMBINATION WITH CYCLOSPORINE OR TACROLIMUS
PLUS METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE (GVHD)
PROPHYLAXIS AFTER HEMATOPOIETIC CELL TRANSPLANTATION
FROM UNRELATED DONORS
Furlong, T., Kiem, H.-P., Appelbaum, F.R., Carpenter, P.A., Deeg, J.,
Doney, K., Flowers, M.E.D., Mielcarek, M., Nash, R.A., Storb, R.,
Martin, P.J. Fred Hutchinson Cancer Research Center, Seattle, WA.
Sirolimus (SIR) is reported to be effective in preventing GVHD
when combined with tacrolimus (TAC) and methotrexate (MTX)
after related and unrelated allogeneic hematopoietic cell transplan-
tation (HCT). In two consecutive clinical trials, we evaluated the ef-
ficacy of SIR plus cyclosporine (CSP Group) or TAC (TAC Group)
and MTX after unrelated HCT. SIR was administered as a 12 mg
PO loading dose on day -1 (CSP Group) or -3 (TAC Group) fol-
lowed by 4 mg PO QD. SIR levels were targeted at 4–14 ng/mL
in the CSP Group and 3–12 ng/mL in the TAC Group. The dose
of CSP was 1.5 mg/kg Q12h IV starting on day -1, and the dose
of TAC was 0.02 mg/kg/day IV starting on day -3. CSP was targeted
at 150–450 ng/mL and TAC at 5–10 ng/mL. All patients received
MTX 5 mg/m2 IV on days 1, 3, 6 and 11. Nine patients were
